Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928030 · ClinicalTrials.gov registry record · Phase 1
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01928030: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01928030 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928030, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
Primary Outcome
Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered recombinant human hyaluronidase, and judged possibly, probably, or definitely related to treatment
Interventions
- BIOLOGICAL recombinant human hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Why NCT01928030 stopped before completion
NCT01928030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which recombinant human hyaluronidase is the first listed.
NCT01928030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01928030 about?
NCT01928030 is a clinical study titled "Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer". This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
What is the current status of trial NCT01928030?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-12. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01928030?
The interventions under investigation include: recombinant human hyaluronidase (BIOLOGICAL).
Who is sponsoring clinical trial NCT01928030?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01928030's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia